Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

83 participants

Study Classification

OBSERVATIONAL

Study Start Date

2001-03-31

Study Completion Date

2003-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer.

PURPOSE: Genetic study to learn more about genes involved in the development of central nervous system tumors in young children.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetic Study of Brain Tumors in Young Children

NCT00010101

Central Nervous System Tumor, Pediatric

TERMINATED

Neurofibromatosis Type 1 Brain Tumor Genetic Risk

NCT01707836

Neurofibromatosis Type 1 Pediatric Brain Tumor

COMPLETED

Neonatal Seizure Registry, GEnetics of Post-Neonatal Epilepsy

NCT05361070

Neonatal Seizure Hypoxic-Ischemic Encephalopathy Stroke +3 more

ACTIVE_NOT_RECRUITING

Genetics of Neonatal Encephalopathy and Related Disorders

NCT07165938

Neonatal Encephalopathy Hypoxic Ischaemic Encephalopathy (HIE)

NOT_YET_RECRUITING

Genomics, Single Nucleotide Polymorphisms (SNPs), and Clinical Neonatology

NCT00315263

Lung Disease Brain Injury Necrotizing Enterocolitis +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

* Identify known genes that have significantly different levels of expression, using microarray gene chip analysis, in infants with newly diagnosed metastatic vs non-metastatic embryonal central nervous system tumors.
* Determine the protein expression of genes identified by microarray analysis that are involved in cellular functions that regulate angiogenesis, invasion, or metastasis in this patient population.
* Determine the quantity of gene expression of the confirmed translationally expressed genes using semi-quantitative polymerase chain reaction.

OUTLINE: This is a multicenter study.

Tumor samples are analyzed using microarray gene chip analysis. Differentially expressed genes are evaluated for protein expression by standard immunohistochemistry and/or Western blot analysis, and gene expression is further quantified by semi-quantitative polymerase chain reaction.

PROJECTED ACCRUAL: Approximately 80-100 patients (20-25 with metastatic disease and 60-75 with non-metastatic disease) will be accrued for this study within 4-5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Central Nervous System Embryonal Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Newly diagnosed embryonal tumors

The participants in this study are infants (\< 3 years of age) with newly diagnosed medulloblastoma, primitive neuroectodermal tumor, or other embryonal tumor, atypical teratoid/rhabdoid tumor, intracranial germ cell tumor, or choroid plexus carcinoma who have received no prior therapy with the exception of steroids and have consented to allow research studies on banked tissue specimens

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Histologically confirmed, newly diagnosed, primary intracranial embryonal central nervous system tumor

* Medulloblastoma
* Primitive neuroectodermal tumor
* Medulloepithelioma
* Ependymoblastoma
* Neuroblastoma
* Pineoblastoma
* Atypical teratoid/rhabdoid tumor
* Intracranial germ cell tumor
* Choroid plexus carcinoma
* M positive ependymoma
* Potential enrollment on PBTC-001 therapeutic protocol

PATIENT CHARACTERISTICS:

Age:

* Under 3

Performance status:

* Not specified

Life expectancy:

* Not specified

Hematopoietic:

* Not specified

Hepatic:

* Not specified

Renal:

* Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

* Not specified

Chemotherapy:

* No prior chemotherapy

Endocrine therapy:

* Prior steroids allowed

Radiotherapy:

* No prior radiotherapy

Surgery:

* Not specified

Other:

* No concurrent investigational agents

Maximum Eligible Age

2 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No